ACRX News and Press, AcelRx Pharmaceuticals Inc. From 03/14/22

AcelRx Pharmaceuticals (ACRX -15.1%) was downgraded by H.C. Wainwright to Neutral from Buy without a price target following its Q4 results last week. The company lost -20.64% on March 11, the day after its Q4 results on March 10 post market. Analyst Ed Arce said the company reported...

AcelRx Pharmaceuticals (ACRX -14.2%) stock fell following its Q4 results. Q4 total revenue declined to $2K, compared to $738K in Q4 2020. The company said 8.96K units of opioid pain drug DSUVIA were sold in Q4 2021, compared to 3.71K units in Q3 2021, but it recognized only $2K in net re...

AcelRx Pharmaceuticals, Inc. (ACRX) Q4 2021 Earnings Conference Call March 10, 2022 16:30 ET Company Participants Raffi Asadorian - Chief Financial Officer Vincent Angotti - Chief Executive Officer Pamela Palmer - Chief Medical Officer Lakhmir Chawla - Chief Medical Officer, Silver Creek Phar...

AcelRx Pharmaceuticals press release (NASDAQ:ACRX): Q4 GAAP EPS of -$0.06 beats by $0.01. Revenue of $0.2M (-73.0% Y/Y) misses by $1.65M. For further details see: AcelRx Pharmaceuticals GAAP EPS of -$0.06 beats by $0.01, revenue of $0.2M misses by $1.65M

AcelRx Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results <span class="legendSpanClass">AcelRx expanded late-stage pipeline with Niyad™ (nafamostat), which has received Breakthrough Designation status from the FDA and an ICD-10 procedural co...

AcelRx Pharmaceuticals (NASDAQ:ACRX) is scheduled to announce Q4 earnings results on Thursday, March 10th, after market close. The consensus EPS Estimate is -$0.07 (+30.0% Y/Y) and the consensus Revenue Estimate is $1.85M (+150.0% Y/Y). Over the last 3 months, EPS and revenue estimates have s...

AcelRx to Host Fourth Quarter and Full Year 2021 Financial Results Call and Webcast on March 10, 2022 PR Newswire HAYWARD, Calif. , March 3, 2022 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company, today announced that...

AcelRx Pharmaceuticals (ACRX +3.9%) announced real-world data for sufentanil sublingual tablet (SST) for pain management in patients undergoing awake plastic surgery showing a rapid recovery time and minimal side effects. The company's drug Dsuvia (sufentanil sublingual tablet), 30 ...

AcelRx Pharmaceuticals Announces Publication of Clinical Data on the Use of Sufentanil Sublingual Tablet during Awake Plastic Surgery Procedures Study concluded that awake plastic surgery procedures can be performed using sublingual sufentanil tablet (30 mcg) with minimal side e...

AcelRx Pharmaceuticals Announces Publication of an Article Highlighting the Utility of the Sufentanil Sublingual Tablet in Pain Medicine Procedures PR Newswire HAYWARD, Calif. , Jan. 27, 2022 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), a specialt...